Search Result

Results for "

PPARα agonists

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) Adenosine Receptor (1) Amyloid-β (2) Antibiotic (2) Apoptosis (1) ATP Citrate Lyase (1) Autophagy (9) Bacterial (6) Cannabinoid Receptor (1) COX (2) Cytochrome P450 (6) Drug Intermediate (1) Endogenous Metabolite (5) ERK (2) Estrogen Receptor/ERR (1) Fatty Acid Synthase (FASN) (1) Free Fatty Acid Receptor (3) Fungal (3) HIF/HIF Prolyl-Hydroxylase (2) IKK (1) Influenza Virus (1) Interleukin Related (2) Isotope-Labeled Compounds (10) JNK (2) Keap1-Nrf2 (1) Ligands for Target Protein for PROTAC (1) NF-κB (3) NO Synthase (2) NOD-like Receptor (NLR) (1) Phosphatase (2) PPAR (116) Pyroptosis (1) RAR/RXR (2) Reactive Oxygen Species (ROS) (3) Reference Standards (16) Sirtuin (1) SOD (3) Stearoyl-CoA Desaturase (SCD) (1) STING (1) TGF-beta/Smad (2) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (18) Cardiovascular Disease (34) Endocrinology (1) Infection (7) Inflammation/Immunology (34) Metabolic Disease (87) Neurological Disease (6)

By Targets:

17β-HSD (1)

Adenosine Receptor (1)

Amyloid-β (2)

Antibiotic (2)

Apoptosis (1)

ATP Citrate Lyase (1)

Autophagy (9)

Bacterial (6)

Cannabinoid Receptor (1)

COX (2)

Cytochrome P450 (6)

Drug Intermediate (1)

Endogenous Metabolite (5)

ERK (2)

Estrogen Receptor/ERR (1)

Fatty Acid Synthase (FASN) (1)

Free Fatty Acid Receptor (3)

Fungal (3)

HIF/HIF Prolyl-Hydroxylase (2)

IKK (1)

Influenza Virus (1)

Interleukin Related (2)

Isotope-Labeled Compounds (10)

JNK (2)

Keap1-Nrf2 (1)

Ligands for Target Protein for PROTAC (1)

NF-κB (3)

NO Synthase (2)

NOD-like Receptor (NLR) (1)

Phosphatase (2)

PPAR (116)

Pyroptosis (1)

RAR/RXR (2)

Reactive Oxygen Species (ROS) (3)

Reference Standards (16)

Sirtuin (1)

SOD (3)

Stearoyl-CoA Desaturase (SCD) (1)

STING (1)

TGF-beta/Smad (2)

Toll-like Receptor (TLR) (1)

By Research Areas:

Cancer (18)

Cardiovascular Disease (34)

Endocrinology (1)

Infection (7)

Inflammation/Immunology (34)

Metabolic Disease (87)

Neurological Disease (6)

124

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16995

Pirinixic acid Maximum Cited Publications 33 Publications Verification Wy-14643	PPAR	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Wy-14643) is a potent agonist of *PPARα, with EC₅₀s of 0.63 μM, 32 μM for murine PPARα* and PPARγ, and 5.0 μM, 60 μM, 35 μM for human *PPARα, PPARγ and PPAR*δ, respectively.

HY-13861

GW7647 20+ Cited Publications	PPAR	Cardiovascular Disease
GW7647 is a potent *PPARα* agonist, with EC₅₀s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-17618

Pemafibrate 5+ Cited Publications (R)-K-13675	PPAR	Cardiovascular Disease Inflammation/Immunology
Pemafibrate is a highly selective *PPARα* agonist, with an EC₅₀ of 1 nM.

HY-107542

Oleoylethanolamide 3 Publications Verification N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide	Endogenous Metabolite PPAR	Cardiovascular Disease Metabolic Disease
Oleoylethanolamide is a high affinity endogenous *PPAR-α* agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-B0637

Bezafibrate 10+ Cited Publications BM15075	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPAR*δ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-19522

Seladelpar 1 Publications Verification MBX-8025; RWJ-800025	PPAR	Metabolic Disease
Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC₅₀ of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .

HY-19937

Saroglitazar 5+ Cited Publications	PPAR	Metabolic Disease
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-13928

GW0742 15+ Cited Publications GW610742	PPAR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 is a potent PPARβ and PPARδ agonist, with an IC₅₀ of 1 nM for human PPARδ in binding assay, and EC₅₀s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.

HY-17444

Tesaglitazar	PPAR	Metabolic Disease Cancer
Tesaglitazar is a dual-target PPARα/γ agonist with an EC₅₀ of 13.4 μM for rat PPARα and 3.6 μM for human PPARα. Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain .

HY-N0783

Eupatilin Maximum Cited Publications 8 Publications Verification	PPAR Autophagy	Neurological Disease Inflammation/Immunology Cancer
Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi Lévl. et Van., is a PPARα* agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.*

HY-106266

Chiglitazar 1 Publications Verification Carfloglitazar	PPAR	Metabolic Disease
Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

HY-19937A

Saroglitazar magnesium 5+ Cited Publications	PPAR	Metabolic Disease
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-14928

Lobeglitazone	PPAR ERK JNK TGF-beta/Smad NO Synthase COX NF-κB Interleukin Related	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone is the orally active agonist for *PPAR* with EC₅₀ of 137.4 nM and 546.3 nM for PPARγ and *PPARα. Lobeglitazone is the inhibitor for ERK/JNK/Smad/NF-κB* signaling pathway. Lobeglitazone exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties .

HY-B0287

Clofibrate 4 Publications Verification	PPAR	Metabolic Disease
Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ～500 μM for murine PPARα* and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.

HY-N6869

Dehydroabietic acid 1 Publications Verification	Antibiotic PPAR Bacterial Fungal	Infection Metabolic Disease Inflammation/Immunology Cancer
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual *PPAR-α/γ* agonist and *PPAR-γ* partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-W081067

Perfluoro(2-methyl-3-oxahexanoic) acid HFPO-DA	PPAR	Infection
Perfluoro (2-methyl-3-oxahexanoic) acid (HFPO-DA) is an orally active *PPARα* agonist with an EC₅₀ of 2.1 μM for human *PPARα*. Perfluoro (2-methyl-3-oxahexanoic) acid induces peroxisome proliferation and increases the levels of proinflammatory mediators. It impairs intestinal barrier function and disrupts cecal flora balance. Perfluoro (2-methyl-3-oxahexanoic) acid is applicable to research related to developmental toxicity, hepatotoxicity and intestinal toxicity .

HY-112813

TUG-1375 4 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pK_i of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ .

HY-14817

Indeglitazar PPM 204	PPAR	Metabolic Disease
Indeglitazar (PPM 204) is an orally available *PPAR* pan-agonist for all three PPARα, PPARδ and PPARγ .

HY-10678

BMS-687453 3 Publications Verification	PPAR	Cardiovascular Disease
BMS-687453 is a potent and selective *PPARα* agonist, with an EC₅₀ and IC₅₀ of 10 nM and 260 nM for human *PPARα* and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.

HY-17445

Muraglitazar BMS-298585	PPAR	Metabolic Disease
Muraglitazar is a PPAR α/γ dual agonist for the research of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα (EC₅₀ = 320 nM) and PPARγ(EC₅₀ = 110 nM) .

HY-50665

LY518674 LY-674	PPAR	Metabolic Disease
LY518674 is a potent, selective *PPARα* agonist, with an EC₅₀ of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis .

HY-106278

GW 590735 1 Publications Verification	PPAR	Metabolic Disease
GW 590735 is a potent and selective *PPARα* agonist. GW 590735 showsEC₅₀=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a *PPARα* and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-W128156

10-Hydroxystearic acid 10-HSA	PPAR	Inflammation/Immunology
10-Hydroxystearic acid (10-HSA) is a *PPARα* agonist. 10-Hydroxystearic acid stimulates collagen synthesis. 10-Hydroxystearic acid is an anti-aging agent and reduces the appearance of pores and hyperpigmented lesions .

HY-108523

LG100754 UVI 2112	RAR/RXR	Metabolic Disease
LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and *RXR:PPARγ* heterodimers. LG100754 is an insulin sensitizer that functions through RXR .

HY-19383

Ertiprotafib 2 Publications Verification PTP 112	Phosphatase IKK PPAR	Metabolic Disease
Ertiprotafib is an inhibitor of PTP1B, IkB kinase β (IKK-β), and a dual PPARα and PPARβ agonist, with an IC₅₀ of 1.6 μM for PTP1B, 400 nM for IKK-β, an EC₅₀ of ~1 μM for PPARα/PPARβ.

HY-19522A

Seladelpar sodium 1 Publications Verification MBX-8025 sodium; RWJ-800025 sodium	PPAR	Metabolic Disease Inflammation/Immunology
Seladelpar (MBX-8025) sodium salt is an orally active, potent and specific PPARδ agonist with an EC₅₀ of 2 nM. Seladelpar sodium salt shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar sodium salt hydrochloride can be used for the study of primary biliary cholangitis .

HY-108571

CP-775146	PPAR	Cardiovascular Disease Metabolic Disease
CP-775146 is a selective *PPARα* agonist (K_i of 24.5 nM) that binds strongly to the PPARα ligand. CP-775146 has no observable affinity for PPARβ and PPARγ.CP-775146 shows hypolipidemic activity. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway .

HY-N9333

Wistin	PPAR	Metabolic Disease Cancer
Wistin, isolated from Caragana sinica roots, is a *PPARα* and PPARγ agonist .

HY-129683

AM3102	PPAR	Metabolic Disease
AM3102 is an oleoylethanolamide (OEA) analog. AM3102 is an endogenous high-affinity PPAR-alpha agonist. AM3102 resists enzymatic hydrolysis, activates PPAR-alpha with high potency in vitro, and persistently reduces feeding when administered in vivo either parenterally or orally .

HY-107542S

Oleoylethanolamide-d4 N-Oleoylethanolamide-d₄; Oleamide MEA-d₄; Oleic acid monoethanolamide-d₄	Isotope-Labeled Compounds Endogenous Metabolite PPAR	Cardiovascular Disease Metabolic Disease
Oleoylethanolamide-d₄ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-107542S2

Oleoylethanolamide-d2 N-Oleoylethanolamide-d₂; Oleamide MEA-d₂; Oleic acid monoethanolamide-d₂	Isotope-Labeled Compounds Endogenous Metabolite PPAR	Cardiovascular Disease Metabolic Disease
Oleoylethanolamide-d₂ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-143239

PPARα/γ agonist 1	PPAR	Metabolic Disease
PPARα/γ agonist 1 (compound 5b) is a potent and dual PPARα/γ partial agonist with EC₅₀ values of 28 nM and 69 nM for PPARα and PPARγ, respectively. PPARα/γ agonist 1 is a promising prototype for dyslipidemia and diabetes research .

HY-110118

Edaglitazone	PPAR	Metabolic Disease
Edaglitazone is a potent, selective and orally active PPARγ agonist, with EC₅₀s of 35.6 nM and 1053 nM for *PPARα* and PPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity .

HY-17618S

Pemafibrate-d4 (R)-K-13675-d₄	PPAR Isotope-Labeled Compounds	Inflammation/Immunology
Pemafibrate-d₄ is deuterated labeled Pemafibrate (HY-17618). Pemafibrate is a highly selective PPARα agonist, with an EC₅₀ of 1 nM.

HY-B0637S

Bezafibrate-d6	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-163547

PPAR agonist 5	PPAR	Inflammation/Immunology
PPAR agonist 5 (compound 4b) is a potent *PPAR* agonist with EC₅₀ values of 3.20, 1.51, 1.92 µM for PPARα, PPARβ/δ, PPARγ, respectively. PPAR agonist 5 shows anti-inflammatory effect .

HY-107542R

Oleoylethanolamide (Standard) N-Oleoylethanolamide (Standard); Oleamide MEA (Standard); Oleic acid monoethanolamide (Standard)	Reference Standards Endogenous Metabolite PPAR	Cardiovascular Disease Metabolic Disease
Oleoylethanolamide (Standard) is the analytical standard of Oleoylethanolamide. This product is intended for research and analytical applications. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-144111

PPARα/δ agonist 1	PPAR	Inflammation/Immunology
PPARα/δ agonist 1 is a potent PPARα/PPARδ dual agonist (PPARα EC₅₀=7.0 nM; PPARδ EC₅₀=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC₅₀=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .

HY-113820

AZD4619	PPAR	Metabolic Disease
AZD4619 is an orally active, selective peroxisome proliferator-activated receptor α (PPARα) agonist. AZD4619 increases alanine aminotransferase 1 (ALT1) protein expression in a dose-dependent manner in human, but not in rat primary hepatocytes. AZD4619 is a lipid-lowering drug .

HY-N9768

(10E,12E)-9-Oxo-10,12-octadecadienoic acid 9-oxo-ODA	Fungal PPAR	Infection
(10E,12E)-9-Oxo-10,12-octadecadienoic acid (9-oxo-ODA) is a *PPARα* agonist that can be isolated from the basidiomycete Gomphus floccosus. (10E,12E)-9-Oxo-10,12-octadecadienoic acid enhances fatty acid oxidation through PPARα activation, thereby inhibiting triglyceride accumulation. (10E,12E)-9-Oxo-10,12-octadecadienoic acid also has antifungal (Fungal) activity .

HY-139177

PPARα agonist 2	PPAR	Cardiovascular Disease
PPARα agonist 2 (compound 4u) is a potent and selective *PPARα* agonist with an EC₅₀ of 37 nM. PPARα agonist 2 exhibits >2,700-fold selectivity for PPARα over other PPAR isoforms. PPARα agonist 2 has the potential for retinal disorders research .

HY-B0287R

Clofibrate (Standard) 4 Publications Verification	Reference Standards PPAR	Metabolic Disease
Clofibrate (Standard) is the analytical standard of Clofibrate. This product is intended for research and analytical applications. Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ～500 μM for murine PPARα* and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.

HY-19848

Cevoglitazar LBM-642	PPAR	Metabolic Disease
Cevoglitazar (LBM-642) is an orally active and highly potent *PPARα* and PPARγ dual agonist. Cevoglitazar can reduce food intake, body weight, and fasting plasma insulin in obese mice and cynomolgus monkeys. Cevoglitazar has the potential for diabetes and obesity-related disorders research .

HY-Y1624

1,1'-(Azodicarbonyl)-dipiperidine ADDP; SR 4077	Free Fatty Acid Receptor PPAR	Metabolic Disease
1,1'-(Azodicarbonyl)-dipiperidine (ADDP) can be used in the condensation reaction of alcohols with acidic compounds. 1,1'-(Azodicarbonyl)-dipiperidine can also be used in the synthesis of GPR120 agonists with antidiabetic activity, as well as the synthesis of triple agonists for *PPARα, PPARγ, and PPAR*δ. 1,1'-(Azodicarbonyl)-dipiperidine can be used in metabolic disease research .

HY-19852

KRP-105	PPAR	Metabolic Disease
KRP-105 is a potent, highly selective, and orally effective PPAR alpha (EC₅₀ = 8 nM) agonist. KRP-105 can significantly reduce serum triglyceride, total cholesterol, and non high density lipoprotein cholesterol levels. KRP-105 can be used for research on metabolic diseases such as dyslipidemia .

HY-117196

GW 9578 1 Publications Verification	PPAR	Metabolic Disease Inflammation/Immunology
GW9578 is a subtype-selective *PPARα* agonist (EC₅₀s of 5 and 50 nM for murine and human PPAR-α) with potent lipid-lowering activity .

HY-176971

PPARα agonist 6	PPAR	Cardiovascular Disease Metabolic Disease
PPARα agonist 6 (Compound 15) is a *PPARα* agonist. PPARα agonist 6 can be used in the research of dyslipidemia .

HY-107054

ESP-31015 ETC-1001	PPAR	Cardiovascular Disease
ESP-31015 (ETC-1001) is an orally active and non-fibrate based *PPARα* agonists. ESP-31015 demonstrates significant lipid-regulating effects in the obese Zucker rat model. ESP-31015 can be used in cardiovascular disease research .

HY-U00014

AVE-8134	PPAR	Metabolic Disease
AVE-8134 is a potent *PPARα* agonist, with EC₅₀ values of 100 and 3000 nM for human and rodent PPARα receptor, respectively.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107542

Oleoylethanolamide 3 Publications Verification N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide	Cardiovascular Disease Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite PPAR
Oleoylethanolamide is a high affinity endogenous *PPAR-α* agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-N0783

Eupatilin Maximum Cited Publications 8 Publications Verification	Flavonoids Neurological Disease Classification of Application Fields Flavones Plants Compositae Disease Research Fields Sindora sumatrana Miq. Cancer	PPAR Autophagy
Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi Lévl. et Van., is a PPARα* agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.*

HY-N0234

Bavachinin Maximum Cited Publications 8 Publications Verification 7-O-Methylbavachin; Bavachinin A	Monophenols Flavonoids Classification of Application Fields Leguminosae Flavonones Phenols Psoralea corylifolia L. Plants Inflammation/Immunology Disease Research Fields Source Classification	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N1990

Gypenoside XLIX 2 Publications Verification	Cardiovascular Disease Triterpenes Structural Classification Classification of Application Fields Terpenoids Cucurbitaceae Plants Gynostemma pentaphyllum (Thunb.) Makino Disease Research Fields Source Classification	PPAR Sirtuin Keap1-Nrf2 Toll-like Receptor (TLR) NF-κB Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Apoptosis Pyroptosis Autophagy
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a K_a value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a *PPAR-α* agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation .

HY-N6869

Dehydroabietic acid 1 Publications Verification	Infection Structural Classification Microorganisms other families Classification of Application Fields Anti-aging Terpenoids Diterpenoids Plants Inflammation/Immunology Disease Research Fields Source Classification	Antibiotic PPAR Bacterial Fungal
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual *PPAR-α/γ* agonist and *PPAR-γ* partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-N9333

Wistin	Flavonoids other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Isoflavones Source Classification	PPAR
Wistin, isolated from Caragana sinica roots, is a *PPARα* and PPARγ agonist .

HY-107542R

Oleoylethanolamide (Standard) N-Oleoylethanolamide (Standard); Oleamide MEA (Standard); Oleic acid monoethanolamide (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite PPAR
Oleoylethanolamide (Standard) is the analytical standard of Oleoylethanolamide. This product is intended for research and analytical applications. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-N9768

(10E,12E)-9-Oxo-10,12-octadecadienoic acid 9-oxo-ODA	Microorganisms Ketones, Aldehydes, Acids Source Classification	Fungal PPAR
(10E,12E)-9-Oxo-10,12-octadecadienoic acid (9-oxo-ODA) is a *PPARα* agonist that can be isolated from the basidiomycete Gomphus floccosus. (10E,12E)-9-Oxo-10,12-octadecadienoic acid enhances fatty acid oxidation through PPARα activation, thereby inhibiting triglyceride accumulation. (10E,12E)-9-Oxo-10,12-octadecadienoic acid also has antifungal (Fungal) activity .

HY-N0783R

Eupatilin (Standard)	Flavonoids Neurological Disease Classification of Application Fields Plants Compositae Disease Research Fields Sindora sumatrana Miq. Source Classification Cancer	Reference Standards PPAR Autophagy
Eupatilin (Standard) is the analytical standard of Eupatilin. This product is intended for research and analytical applications. Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi Lévl. et Van., is a PPARα* agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.*

HY-N6869R

Dehydroabietic acid (Standard)	Structural Classification Microorganisms other families Terpenoids Diterpenoids Plants Source Classification	Antibiotic Reference Standards PPAR Bacterial Fungal
Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-N0234R

Bavachinin (Standard) 7-O-Methylbavachin (Standard); Bavachinin A (Standard)	Structural Classification Monophenols Flavonoids Leguminosae Flavonones Phenols Psoralea corylifolia L. Plants Source Classification	Amyloid-β Reference Standards PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

Cat. No.	Product Name	Chemical Structure

HY-17356S

Fenofibrate-d6
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-107542S

Oleoylethanolamide-d4
Oleoylethanolamide-d₄ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-107542S2

Oleoylethanolamide-d2
Oleoylethanolamide-d₂ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-17618S

Pemafibrate-d4
Pemafibrate-d₄ is deuterated labeled Pemafibrate (HY-17618). Pemafibrate is a highly selective PPARα agonist, with an EC₅₀ of 1 nM.

HY-B0637S

Bezafibrate-d6
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-14728S

Deutaleglitazar
Deutaleglitazar (Aleglitazar-d₂) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and PPARγ) .

HY-N6807S

Elemicin-d3
Elemicin-d₃ is deuterated labeled Pemafibrate (HY-17618). Pemafibrate is a highly selective *PPARα* agonist, with an EC₅₀ of 1 nM.

HY-B0287S

Clofibrate-d4
Clofibrate-d₄ is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.

HY-B0637S1

Bezafibrate-d4
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637S2

Bezafibrate-13C6
Bezafibrate- ¹³C₆ (BM15075- ¹³C₆) is ¹³C labeled Bezafibrate. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPAR*δ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-19937S1

Saroglitazar-d4
Saroglitazar-d₄ is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d₄ is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-17356S2

Fenofibrate-13C6
Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective *PPARα* agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-17356S1

Fenofibrate-d4
Fenofibrate-d₄ is the deuterium labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively .

HY-B1415S

Clofibric acid-d4

Clofibric acid-d₄ is the deuterium labeled Clofibric acid (HY-B1415). Clofibric acid also is an herbicideClofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of Escherichia coli. Clofibric acid increases SOD activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17356G

Fenofibrate	Cytochrome P450 PPAR Autophagy	Cardiovascular Disease
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective *PPARα* agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks